"We expect to begin recording product revenue from DARE to PLAY in the third quarter of 2026" (Chief Accounting Officer Haring-Layton), while adding, "Flora Sync LF5 consumer health product revenue is ...

Company Highlights Second Positive DSMB Review of Interim Data from Ovaprene® Phase 3 Clinical Trial, DARE to PLAY™ ...

Niagen Bioscience is back in focus after analysts trimmed their blended price target from US$14 to around US$12.60, signaling a more measured view of potential upside. Research notes describe this ...

Q2 FY26 earnings call highlights: raised revenue guide, AI-enabled drug discovery, AWS partnership, margin and EBITDA outlook.

For generations, St. Louis has been known as a city of makers. Today, some of its most consequential builders work not with brick and steel, but with cells, code, crops, and data. This month, St.

Q1 2026 Management View “Overall, Q1 reflected continued progress on transforming Harvard Bioscience from a traditional tool provider into a leading supplier of the emerging translational science ...

Shift Bioscience is building a cell simulation platform that combines generative AI with its highly accurate, high-throughput biological aging clock, to predict which sets of genes are most likely to ...

Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today expanded its clonal genes portfolio with the early access launch of Complex Genes.

Niagen Bioscience, Inc. (NASDAQ: NAGE) is the global authority in NAD+ (nicotinamide adenine dinucleotide) science and ...

ARK has been selling TWST for days.

View Twist Bioscience Corp. TWST stock quote prices, financial information, real-time forecasts, and company news from CNN.